Lipoprotein (a): when to measure and how to treat?
D Rhainds, MR Brodeur, JC Tardif - Current Atherosclerosis Reports, 2021 - Springer
Abstract Purpose of Review The purpose of this article is to review current evidence for
lipoprotein (a)(Lp (a)) as a risk factor for multiple cardiovascular (CV) disease phenotypes …
lipoprotein (a)(Lp (a)) as a risk factor for multiple cardiovascular (CV) disease phenotypes …
Lipoprotein (a) and cardiovascular disease: sifting the evidence to guide future research
PR Kamstrup, RDG Neely, S Nissen… - European Journal of …, 2024 - academic.oup.com
Abstract Lipoprotein (a)(Lp (a)) is a genetically determined causal risk factor for
cardiovascular disease including coronary heart disease, peripheral arterial disease …
cardiovascular disease including coronary heart disease, peripheral arterial disease …
Lipoprotein (a): a risk factor for atherosclerosis and an emerging therapeutic target
SA Di Fusco, M Arca, P Scicchitano, A Alonzo… - Heart, 2023 - heart.bmj.com
Lipoprotein (a)(Lp (a)) is a complex circulating lipoprotein, and increasing evidence has
demonstrated its role as a risk factor for atherosclerotic cardiovascular disease (ASCVD) …
demonstrated its role as a risk factor for atherosclerotic cardiovascular disease (ASCVD) …
Molecular, population, and clinical aspects of lipoprotein (a): a bridge too far?
NC Ward, KM Kostner, DR Sullivan, P Nestel… - Journal of clinical …, 2019 - mdpi.com
There is now significant evidence to support an independent causal role for lipoprotein
(a)(Lp (a)) as a risk factor for atherosclerotic cardiovascular disease. Plasma Lp (a) …
(a)(Lp (a)) as a risk factor for atherosclerotic cardiovascular disease. Plasma Lp (a) …
Use of Lipoprotein (a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
DP Wilson, TA Jacobson, PH Jones… - Journal of clinical …, 2019 - Elsevier
Abstract Lipoprotein (a)[Lp (a)] is a well-recognized, independent risk factor for
atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in …
atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in …
Lipoprotein (a) as a therapeutic target in cardiovascular disease
M Koschinsky, M Boffa - Expert opinion on therapeutic targets, 2014 - Taylor & Francis
Introduction: Recent advances in genetics and epidemiology have once again thrust
lipoprotein (a)(Lp (a)) into the clinical spotlight. Elevated plasma concentrations of Lp (a) are …
lipoprotein (a)(Lp (a)) into the clinical spotlight. Elevated plasma concentrations of Lp (a) are …
Lipoprotein (a) in clinical practice: A guide for the clinician
C Krittanawong, NS Maitra, AH El-Sherbini… - Progress in …, 2023 - Elsevier
Cardiovascular disease (CVD) remains the leading cause of death worldwide. Serum
lipoprotein (a)(Lp (a)) has been shown to be an independent and causative risk factor for …
lipoprotein (a)(Lp (a)) has been shown to be an independent and causative risk factor for …
Use of Lipoprotein (a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
DP Wilson, TA Jacobson, PH Jones… - Journal of clinical …, 2022 - Elsevier
Lipoprotein (a)[Lp (a)] is a well-recognized, independent risk factor for atherosclerotic
cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the …
cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the …
Lipoprotein (a): a genetic marker for cardiovascular disease and target for emerging therapies
A Cesaro, A Schiavo, E Moscarella… - Journal of …, 2021 - journals.lww.com
Abstract Lipoprotein (a)[Lp (a)] is an established cardiovascular risk factor, and growing
evidence indicates its causal association with atherosclerotic disease because of the …
evidence indicates its causal association with atherosclerotic disease because of the …
Lipoprotein (a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions
Aims To investigate the population attributable fraction due to elevated lipoprotein (a)(Lp (a))
and the utility of measuring Lp (a) in cardiovascular disease (CVD) risk prediction. Methods …
and the utility of measuring Lp (a) in cardiovascular disease (CVD) risk prediction. Methods …